Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Absorption, Distribution, Metabolism and Excretion of [14C] Labelled BIA 5-1058

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04069130
Recruitment Status : Active, not recruiting
First Posted : August 28, 2019
Last Update Posted : August 28, 2019
Sponsor:
Information provided by (Responsible Party):
Bial - Portela C S.A.

Brief Summary:
The purpose of the study is to determine the mass balance recovery in plasma, expired air, urine and faeces after a single oral dose of 400 mg 14C-labeled BIA 5-1058; to provide plasma, urine and faecal samples for metabolite profiling and structural identification; and determine the routes and rates of elimination of [14C]-BIA 5-1058

Condition or disease Intervention/treatment Phase
Cardiovascular Diseases Drug: 400 mg of BIA 5-1058 Phase 1

Detailed Description:
This is a Phase 1, single-dose, single-centre, single period, open-label, absorption, distribution, metabolism and excretion study in 8 healthy adult male subjects. Subjects will receive a single oral dose of 400 mg [14C]-BIA 5-1058, containing not more than (NMT) 4.6 MBq (124 µCi) 14C, as an oral capsule. Subjects will be screened for eligibility to participate in the study between 28 and 2 days before dosing. Eligible subjects will be admitted to the clinical unit on the morning of Day -1 prior to investigational medicinal product (IMP) administration. Subjects will be dosed on the morning of Day 1 after an overnight fast of at least 10 hours and will remain resident in the clinic until up to 336 h after dosing (up to Day 15). Blood, urine, faeces and expired air will be collected at predefined time points for mass balance and PK analysis. It is planned that subjects will be released as a group when all subjects have achieved a mass balance cumulative recovery of >90% or if <1% of the dose administered has been collected in urine, faeces and expired air within 2 separate, consecutive 24 h periods. This may result in the subjects being discharged as a group prior to completion of the planned residency period. Once the discharge criteria or the planned residency period has been achieved, collection of all samples (blood, urine, faeces, and expired air) will be stopped and the subjects will undergo discharge assessments. Subjects who have not met the mass balance discharge criteria on Day 15 will return to the clinical unit for up to five further 24-hour residency periods (Days 21-22 [±1 day], 28-29 [±1 day], 42-43 [±2 days], 56-57 [±2 days] and 77-78 [±3 days]) to collect blood samples for PK analysis and urine and faeces samples for analysis of total radioactivity. If the parent and metabolite are below the limit of quantification at any of these visits, subsequent return visits may be cancelled. If by Day 78, levels are not below the limit of quantification or if the additional 24 h residency periods are not considered appropriate or necessary, then home collections of urine and/or faeces may be requested at the discretion of the investigator for individual subjects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Study to Assess the Absorption, Distribution, Metabolism and Excretion, Including the Mass Balance Recovery, Metabolite Profiling and Identification, of [14C] Labelled BIA 5-1058 Following a Single Oral Dose Administration in Healthy Male Subjects
Actual Study Start Date : April 8, 2019
Estimated Primary Completion Date : September 30, 2019
Estimated Study Completion Date : September 30, 2019

Arm Intervention/treatment
Experimental: BIA 5
single oral dose of 400 mg as an oral capsule
Drug: 400 mg of BIA 5-1058
1 x 400 mg capsule Oral, Fasted




Primary Outcome Measures :
  1. Ae(urine) - amount excreted in urine [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Calculation of Mass balance of total radioactivity

  2. Ae(faeces) - amount excreted in faeces [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Calculation of Mass balance of total radioactivity

  3. Ae(expired air) - amount excreted in expired air [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Calculation of Mass balance of total radioactivity

  4. Ae(total) - amount excreted in urine, faeces and expired air combined [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Calculation of Mass balance of total radioactivity

  5. CumAe(urine) - cumulative amount excreted in urine [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Calculation of Mass balance of total radioactivity

  6. CumAe(faeces) - cumulative amount excreted in faeces [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Calculation of Mass balance of total radioactivity

  7. CumAe(expired air) - cumulative amount excreted in expired air [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Calculation of Mass balance of total radioactivity

  8. CumAe(total) - cumulative amount excreted in urine, faeces and expired air combined [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Calculation of Mass balance of total radioactivity

  9. %Ae(urine) - amount excreted in urine expressed as a percentage of the administered dose [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Calculation of Mass balance of total radioactivity

  10. %Ae(faeces) - amount excreted in faeces expressed as a percentage of the administered dose [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Calculation of Mass balance of total radioactivity

  11. %Ae(expired air) - amount excreted in expired air expressed as a percentage of the administered dose [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Calculation of Mass balance of total radioactivity

  12. %Ae(total) - amount excreted in urine, faeces and expired air combined expressed as a percentage of the administered dose [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Calculation of Mass balance of total radioactivity

  13. Cum%Ae(urine) - cumulative amount excreted in urine expressed as a percentage of the administered dose [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Calculation of Mass balance of total radioactivity

  14. Cum%Ae(faeces) - cumulative amount excreted in faeces expressed as a percentage of the administered dose [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Calculation of Mass balance of total radioactivity

  15. Cum %Ae(expired air) - cumulative amount excreted in expired air expressed as a percentage of the administered dose [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Calculation of Mass balance of total radioactivity

  16. Cum %Ae(total) - cumulative amount excreted in urine, faeces and expired air combined expressed as a percentage of the administered dose [ Time Frame: Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Calculation of Mass balance of total radioactivity

  17. Tmax- the time from dosing at which Cmax was apparent [ Time Frame: Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Pharmacokinetic Data Analysis

  18. Cmax - maximum observed concentration [ Time Frame: Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Pharmacokinetic Data Analysis

  19. C24 - plasma concentration at 24 h [ Time Frame: Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Pharmacokinetic Data Analysis

  20. AUC(0-last) - area under the curve from 0 time to last measurable concentration [ Time Frame: Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Pharmacokinetic Data Analysis

  21. AUC(0-inf) - area under the curve from 0 time extrapolated to infinity [ Time Frame: Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Pharmacokinetic Data Analysis

  22. AUC%extrap - percentage of AUC(0-inf) extrapolated beyond last measured time point [ Time Frame: Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Pharmacokinetic Data Analysis

  23. Lambda-z - the slope of the apparent elimination phase [ Time Frame: Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Pharmacokinetic Data Analysis

  24. Kel - elimination rate constant [ Time Frame: Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Pharmacokinetic Data Analysis

  25. T1/2 - the apparent elimination half-life [ Time Frame: Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Pharmacokinetic Data Analysis

  26. CL/F - total body clearance after extravascular administration (for BIA 5 1058 in plasma only) [ Time Frame: Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Pharmacokinetic Data Analysis

  27. Vz/F - apparent volume of distribution based on the terminal phase after extravascular administration (for BIA 5 1058 in plasma only). [ Time Frame: Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15. ]
    Pharmacokinetic Data Analysis



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy males;
  • Age 30 to 65 years of age, inclusive;
  • Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive;
  • Normal resting supine BP (Systolic BP: 90-140 mmHg [age 18-45] 90 160 mmHg [age >45], Diastolic BP: 40-90 mmHg) and heart rate: 40-90 bpm (age 18-45) 50-90 bpm (age >45) or showing no clinically relevant deviation as judged by the investigator or delegate;
  • Digital (12-lead) ECG recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the investigator or delegate;
  • All values for clinical laboratory tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the investigator or delegate;
  • Must be willing and able to communicate and participate in the whole study;
  • Must have regular bowel movements (ie, average stool production of between ≥1 every 2 days and ≤3 stools per day);
  • Must provide written informed consent;
  • Must agree to adhere to the contraception requirements

Exclusion Criteria:

  • Females;
  • Subjects who have received any IMP in a clinical research study within the previous 90 days prior to Day 1 of the study;
  • Subjects who are study site employees, or immediate family members of a study site or sponsor employee;
  • Subjects who have previously received BIA 5-1058 (including participation in QCL118167);
  • History of any drug or alcohol abuse in the past 2 years;
  • Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of wine, depending on type);
  • Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening and admission;
  • Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months;
  • Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study;
  • Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening;
  • Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator (laboratory parameters are listed in Appendix 2);
  • Positive drugs of abuse test result;
  • Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results;
  • An estimated creatinine clearance of <90 mL/min based on creatinine clearance calculation using the Cockcroft-Gault equation and normalised to an average surface area of 1.73 m2;
  • Clinically significant history of cardiovascular, renal, hepatic, respiratory and particularly GI disease, especially peptic ulceration, GI bleeding, ulcerative colitis, Crohn's Disease or Irritable Bowel Syndrome, as judged by the investigator or sub investigator;
  • Frequent headaches and/or migraine, recurrent nausea, and/or vomiting (more than twice a month);
  • Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients;
  • Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active;
  • Donation or loss of greater than 400 mL of blood within the previous 3 months;
  • Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than 2 g paracetamol per day) or herbal remedies in the 14 days before IMP administration. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the PI and sponsor's medical monitor;
  • Failure to satisfy the investigator of fitness to participate for any other reason.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04069130


Locations
Layout table for location information
United Kingdom
Quotient Sciences
Nottingham, United Kingdom, NG11 6JS
Sponsors and Collaborators
Bial - Portela C S.A.
Layout table for additonal information
Responsible Party: Bial - Portela C S.A.
ClinicalTrials.gov Identifier: NCT04069130    
Other Study ID Numbers: BIA-51058-119
First Posted: August 28, 2019    Key Record Dates
Last Update Posted: August 28, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases